Value
7.1/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 8.8 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 7.9 |
| PEG | 10.0 |
- ▸Forward P/E: 15.4x
- ▸PEG: 0.09
- ▸Attractively valued
ALVO · Why this verdict
Why Alvotech (ALVO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue fell more than 20% year-over-year and has been flagged alongside negative free cash flow as a classic value-trap combination — low price masked by deteriorating fundamentals rather than genuine undervaluation. Bear case | Revenue growth turns positive on a year-over-year basis for 2 consecutive quarters, demonstrating that the top-line contraction has stabilized. | →Stable |
| CounterA forward price-to-earnings multiple near 23 times may already discount the revenue decline; if new product launches or biosimilar approvals stabilize the trajectory, the apparent trap could prove temporary. | ||
Free cash flow is negative at roughly 16% of revenue, meaning the business is consuming cash rather than generating it — a structural concern for a specialty pharmaceutical company without a clear near-term profitability timeline. Quality breakdown | Free cash flow margin turns positive within 12 months, confirming the business can self-fund operations. | →Stable |
| CounterEarly-stage specialty pharmaceutical companies often burn cash during biosimilar approval cycles and product launches; negative free cash flow may reflect investment rather than terminal cash erosion. | ||
The stock trades below its 200-day moving average, and that average itself is declining at roughly 13% over the past 30 days — a confirmed downtrend that historically requires meaningful fundamental improvement before the technical damage reverses. Momentum breakdown | Price closes and holds above the 200-day moving average for more than 20 consecutive trading days, signaling a genuine trend change. | →Stable |
| CounterOn-balance volume is rising, indicating shares are accumulating at these levels; if the improving MACD sustains, a momentum reversal can develop faster than the chart damage alone implies. | ||
Two of the last three quarters with available analyst estimates produced earnings misses — including the most recent quarter, which came in nearly 29% below consensus — establishing a pattern of execution risk at a stage when the company needs to rebuild investor confidence. Earnings | EPS surprise exceeds 5% for 2 consecutive quarters, demonstrating a return to beating expectations consistently. | →Stable |
| CounterThe quarter between the two misses produced a beat of nearly 191%, showing the company can sharply outperform when estimates are set conservatively enough — suggesting high volatility rather than a one-directional trend. | ||
Revenue fell more than 20% year-over-year and has been flagged alongside negative free cash flow as a classic value-trap combination — low price masked by deteriorating fundamentals rather than genuine undervaluation.
→StableBear case
- Expectation
- Revenue growth turns positive on a year-over-year basis for 2 consecutive quarters, demonstrating that the top-line contraction has stabilized.
CounterA forward price-to-earnings multiple near 23 times may already discount the revenue decline; if new product launches or biosimilar approvals stabilize the trajectory, the apparent trap could prove temporary.
Free cash flow is negative at roughly 16% of revenue, meaning the business is consuming cash rather than generating it — a structural concern for a specialty pharmaceutical company without a clear near-term profitability timeline.
→StableQuality breakdown
- Expectation
- Free cash flow margin turns positive within 12 months, confirming the business can self-fund operations.
CounterEarly-stage specialty pharmaceutical companies often burn cash during biosimilar approval cycles and product launches; negative free cash flow may reflect investment rather than terminal cash erosion.
The stock trades below its 200-day moving average, and that average itself is declining at roughly 13% over the past 30 days — a confirmed downtrend that historically requires meaningful fundamental improvement before the technical damage reverses.
→StableMomentum breakdown
- Expectation
- Price closes and holds above the 200-day moving average for more than 20 consecutive trading days, signaling a genuine trend change.
CounterOn-balance volume is rising, indicating shares are accumulating at these levels; if the improving MACD sustains, a momentum reversal can develop faster than the chart damage alone implies.
Two of the last three quarters with available analyst estimates produced earnings misses — including the most recent quarter, which came in nearly 29% below consensus — establishing a pattern of execution risk at a stage when the company needs to rebuild investor confidence.
→StableEarnings
- Expectation
- EPS surprise exceeds 5% for 2 consecutive quarters, demonstrating a return to beating expectations consistently.
CounterThe quarter between the two misses produced a beat of nearly 191%, showing the company can sharply outperform when estimates are set conservatively enough — suggesting high volatility rather than a one-directional trend.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alvotech faces compounding headwinds — revenue declined more than 20% over the past year, free cash flow is negative, and the most recent earnings report missed estimates by nearly 29% — all while the stock trades in a confirmed long-term downtrend; absent a clear catalyst for operational stabilization, the risk/reward is unfavorable.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 2.6 |
| Gross margin | 8.3 |
| Op margin | 3.7 |
| Net margin | 0.0 |
| Current ratio | 6.3 |
| FCF quality | 0.0 |
| Moat | 5.2 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -16% of revenue
- ▸No competitive moat
Growth
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 10.0 |
- ▸Declining revenue: -20%
Momentum
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 3.1 |
| OBV | 1.0 |
| MA position | 3.0 |
| Volume | 0.0 |
- ▸Capitulation risk (RSI 30, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -12.4%/30d — confirmed downtrend
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 6.5 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.70 (n=1)
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 304%
Insider
5.0/10data confidence 50%Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.1 |
| quality rank | 1.5 |
| growth rank | 0.5 |
Technical
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.3 |
| support resistance | 6.8 |
| 52w position | 0.0 |
| gap | 5.0 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.4 |
| days to cover | 5.7 |
| volatility | 0.0 |
| beta | 10.0 |
| news risk | 6.0 |
Catalyst
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:45d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.0<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
13.5%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.2B) below institutional reach
SuitabilitySpeculative — Drawdown -70% (>40% off 52w high)
Investment implication
The F-path SELL output reflects an overall score of 5.1 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 8.2) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.0<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 0.00 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 8.2, Value at 7.1, and Risk (lower is worse) at 6.0; the weakest are Momentum at 2.0, Peer rank at 3.0, and Quality at 4.1. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue Decline Value Trap
Trip ifRevenue growth exceeds 0% year-over-year for 2 consecutive quarters.
- P2Negative Free Cash Flow
Trip ifFree cash flow margin rises above 0% for 2 consecutive quarters.
- P3Confirmed Price Downtrend
Trip ifPrice closes above the 200-day moving average for more than 20 consecutive trading days.
- P4Consecutive Earnings Misses
Trip ifEPS surprise exceeds 10% for 2 consecutive quarters.